Post by icemandios on Sept 30, 2021 13:00:06 GMT
Phio Pharmaceuticals Announces Two Upcoming Data Presentations at Scientific Conferences in October 2021
PR Newswire
MARLBOROUGH, Mass. , Sept. 30, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL ™ ) therapeutic platform, today announced two poster presentations at upcoming scientific conferences scheduled to take place in October 2021 . These presentations include an abstract being presented by the Phio team at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, which is being held from October 7-10, 2021 ; and a poster presentation of data from a study using INTASYL by the Company's collaborators at Helmholtz Zentrum München (HMGU) at the 8th Immunotherapy of Cancer Conference (ITOC8), which is being held from Oct. 8–9, 2021.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows:
Event: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Title: Targeting BRD4 in T cells with self-delivering RNAi PH-894 for immunotherapy
Authors: Melissa Maxwell , et al.
Date: October 7-10, 2021
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here) .
Event: 8th Immunotherapy of Cancer Conference (ITOC8)
Title: Targeting Diaclyglycerol Kinase alpha and zeta by self-delivering RNAi to optimize T lymphocytes for adoptive therapy of solid tumors
Authors: Anna Herbstritt, et al.
Abstract Number: P01.03
Date: October 8-9, 2021
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL ™ ) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , Sept. 30, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL ™ ) therapeutic platform, today announced two poster presentations at upcoming scientific conferences scheduled to take place in October 2021 . These presentations include an abstract being presented by the Phio team at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, which is being held from October 7-10, 2021 ; and a poster presentation of data from a study using INTASYL by the Company's collaborators at Helmholtz Zentrum München (HMGU) at the 8th Immunotherapy of Cancer Conference (ITOC8), which is being held from Oct. 8–9, 2021.
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows:
Event: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Title: Targeting BRD4 in T cells with self-delivering RNAi PH-894 for immunotherapy
Authors: Melissa Maxwell , et al.
Date: October 7-10, 2021
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here) .
Event: 8th Immunotherapy of Cancer Conference (ITOC8)
Title: Targeting Diaclyglycerol Kinase alpha and zeta by self-delivering RNAi to optimize T lymphocytes for adoptive therapy of solid tumors
Authors: Anna Herbstritt, et al.
Abstract Number: P01.03
Date: October 8-9, 2021
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL ™ ) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .